{
    "clinical_study": {
        "@rank": "146427", 
        "acronym": "DOL-ART", 
        "arm_group": {
            "arm_group_label": "Dolutegravir", 
            "description": "Prospective, non-interventional study of the use of doluetegravir as part of an antiretroviral combination therapy in routine daily practice in Germany. No drug will be provided. No study visits or procedures are mandated per protocol."
        }, 
        "brief_summary": {
            "textblock": "DOL-ART is a multi-center, prospective, non-interventional study of the use of doluetegravir\n      as part of an antiretroviral combination therapy in routine daily practice in Germany. The\n      primary study objective is a descriptive characterization of the frequency of therapeutic\n      monitoring measures in HIV-infected patients under dolutegravir-containing ART in routine\n      daily practice in Germany.\n\n      The study is designed to enroll approximately 400 patients. There are no protocol-mandated\n      visits or procedures associated with the study. Each patient is expected to participate for\n      a maximum of 3 years or until premature discontinuation (i.e., discontinuation of\n      dolutegravir, due to death, withdrawal of consent, lost to follow-up)."
        }, 
        "brief_title": "A Prospective, Non-interventional Study of the Use of Dolutegravir as Part of Combination Antiretroviral Therapy in Routine Daily Practice in Germany", 
        "completion_date": {
            "#text": "December 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Infection, Human Immunodeficiency Virus", 
        "condition_browse": {
            "mesh_term": [
                "Acquired Immunodeficiency Syndrome", 
                "HIV Infections", 
                "Immunologic Deficiency Syndromes"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Documented HIV infection\n\n          -  Age \u2265 18 years\n\n          -  Decision for the first initiation of dolutegravir as part of an ART by the attending\n             physician irrespective of inclusion in this observational study\n\n          -  Prior to the start of this study, the patient must have been receiving a\n             dolutegravir-containing ART for at least 4 weeks\n\n        Exclusion Criteria:\n\n          -  Discontinuation of dolutegravir as part of an ART prior to the start of the study\n             documentation\n\n          -  Participation in a clinical trial during this study\n\n          -  Participation in a clinical trial or compassionate use program with dolutegravir\n             being or having been part of the investigational medication"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Approximately 40 HIV treatment centers in Germany are planned to be involved in the\n        documentation.  The participating study site will document a maximum of 20 patients for\n        this observation study.  Overall, approximately 400 patients under dolutegravir-containing\n        ART are to be documented.  This selection process is intended to achieve the documentation\n        of patients under dolutegravir-containing ART in routine daily practice representative for\n        Germany."
            }
        }, 
        "enrollment": {
            "#text": "400", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 20, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02076386", 
            "org_study_id": "201067"
        }, 
        "intervention": {
            "arm_group_label": "Dolutegravir", 
            "description": "Prospective, non-interventional study of the use of doluetegravir as part of an antiretroviral combination therapy in routine daily practice in Germany. No drug will be provided. No study visits or procedures are mandated per protocol.", 
            "intervention_name": "Dolutegravir", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "February 27, 2014", 
        "number_of_groups": "1", 
        "official_title": "A Prospective, Non-interventional Study of the Use of Dolutegravir as Part of Combination Antiretroviral Therapy in Routine Daily Practice in Germany (DOL-ART)", 
        "overall_contact": {
            "email": "GSKClinicalSupportHD@gsk.com", 
            "last_name": "US GSK Clinical Trials Call Center", 
            "phone": "877-379-3718"
        }, 
        "overall_official": {
            "affiliation": "ViiV Healthcare", 
            "last_name": "GSK Clinical Trials", 
            "role": "Study Director"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Germany: BfArM", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Descriptive characterization of the frequency of therapeutic monitoring measures in HIV-infected patients under dolutegravir-containing ART in routine daily practice in Germany.", 
            "measure": "Frequency of therapeutic monitoring measures in HIV-infected patients", 
            "safety_issue": "No", 
            "time_frame": "up to 3 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02076386"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Type of the therapeutic monitoring measures", 
                "safety_issue": "No", 
                "time_frame": "up to 3 years"
            }, 
            {
                "description": "To evaluate the frequency and type of serious adverse events and drug-related adverse events in patients treated with dolutegravir.", 
                "measure": "Number of participants with Serious Adverse Events and drug-related adverse events as a measure of safety and tolerability", 
                "safety_issue": "No", 
                "time_frame": "up to 3 years"
            }, 
            {
                "description": "Defined as viral load < 50 copies/ml", 
                "measure": "Efficacy", 
                "safety_issue": "No", 
                "time_frame": "from start of dolutegravir up to 3 years"
            }, 
            {
                "description": "To characterise resistance profile in case of virological failure", 
                "measure": "Resistance profile", 
                "safety_issue": "No", 
                "time_frame": "from start of dolutegravir up to 3 years"
            }, 
            {
                "description": "To evaluate the change in patient satisfaction relative to baseline in patients treated with dolutegravir", 
                "measure": "Patient satisfaction", 
                "safety_issue": "No", 
                "time_frame": "Up to 3 years from baseline"
            }, 
            {
                "measure": "Reasons for selecting dolutegravir-containing ART", 
                "safety_issue": "No", 
                "time_frame": "Baseline"
            }, 
            {
                "measure": "Reasons for discontinuing dolutegravir-containing ART", 
                "safety_issue": "No", 
                "time_frame": "Up to 3 years after baseline"
            }
        ], 
        "source": "ViiV Healthcare", 
        "sponsors": {
            "collaborator": {
                "agency": "GlaxoSmithKline", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "ViiV Healthcare", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "February 2014"
    }
}